Resonance Health Ltd
ASX:RHT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
Hachijuni Bank Ltd
TSE:8359
|
JP |
Resonance Health Ltd
Research & Development
Resonance Health Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Resonance Health Ltd
ASX:RHT
|
Research & Development
-AU$697.3k
|
CAGR 3-Years
5%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
-17%
|
|
|
Somnomed Ltd
ASX:SOM
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cochlear Ltd
ASX:COH
|
Research & Development
-AU$299.9m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-8%
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Research & Development
-AU$5.2m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-15%
|
|
|
Austco Healthcare Ltd
ASX:AHC
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Research & Development
-AU$3.9m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
Resonance Health Ltd
Glance View
Resonance Health Ltd. operates as a healthcare company, which involves in the development and commercialization of technologies and services for the quantitative analysis of radiological images in a regulated and quality controlled environment. The company is headquartered in Perth, Western Australia. The firm is focused on the development and commercialization of technologies and services for the analysis of radiological images. The firm's core product is FerriScan, which is a non-invasive liver diagnostic technology used for the measurement of iron in the liver. FerriScan uses Artificial Intelligence (AI) as an automated software medical device to determine liver iron concentration (LIC) measurement from magnetic resonance imaging (MRI) scans of a patient's liver. The firm product HepaFat-Scan is a non-invasive MRI-based solution for measuring the volume fraction of fat in liver tissue. HepaFat-Scan is a medical device software, which is fully automated and uses Artificial Intelligence (AI) to assess liver fat. HepaFat-AI assesses and reports the volumetric liver fat fraction (VLFF), proton density fat fraction (PDFF), and steatosis grade in individuals with suspected fatty liver disease.
See Also
What is Resonance Health Ltd's Research & Development?
Research & Development
-697.3k
AUD
Based on the financial report for Dec 31, 2025, Resonance Health Ltd's Research & Development amounts to -697.3k AUD.
What is Resonance Health Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
-17%
Over the last year, the Research & Development growth was 15%. The average annual Research & Development growth rates for Resonance Health Ltd have been 5% over the past three years , -42% over the past five years , and -17% over the past ten years .
